PD 198306 NEW
| Price | $58 | $141 | $198 |
| Package | 1mg | 5mg | 10mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2025-09-11 |
Product Details
| Product Name: PD 198306 | CAS No.: 212631-61-3 |
| Purity: 99.75% | Supply Ability: 10g |
| Release date: 2025/09/11 |
Product Introduction
Bioactivity
| Name | PD 198306 |
| Description | PD 198306 is a selective inhibitor of MAPK/ERK-kinase (MEK) with antihyperalgesic effects. PD 198306 reduces the Streptozocin-induced increase in the level of active ERK1. |
| In vitro | PD 198306 (10 μM) reduces Tha-Crimson replication by 30% at 18 h and 50% at 36 h. PD 198306 (10 μM) significantly inhibits Tha-GFP replication by 25%[1]. |
| In vivo | In male Sprague Dawley rats bearing neuropathic pain, PD 198306 (1-30 μg/10 μL; i.t.) dose-dependently blocks static allodynia in both the chronic constriction injury and the streptozocin models[2]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 45 mg/mL (94.49 mM), Sonication is recommended. |
| Keywords | screening | RNA | rabies | phosphate | phosphatases | PD-198306 | PD198306 | PD 198306 | pain | neuropathic | Mitogen-activated protein kinase kinase | mitogen-activated protein | MEK | MAPKK | MAPK | MAP2K | kinases | interference | inositol | Inhibitor | inhibit | ERK | drug | antihyperalgesic |
| Inhibitors Related | Lidocaine | Refametinib R enantiomer | Binimetinib | Lidocaine hydrochloride | U0126-EtOH | Selumetinib | Refametinib | Honokiol | Pelitinib | Trametinib | PD184161 | PD98059 |
| Related Compound Libraries | Anti-Colorectal Cancer Compound Library | Bioactive Compound Library | Pain-Related Compound Library | Kinase Inhibitor Library | Anti-Ovarian Cancer Compound Library | Inhibitor Library | Anti-Prostate Cancer Compound Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | Anti-Cancer Compound Library | Anti-Liver Cancer Compound Library | MAPK Inhibitor Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $0.00/10mg |
VIP8Y
|
Guangzhou PI PI BIOTECH INC
|
2020-06-12 | |
| $1.00/1g |
VIP5Y
|
RongNa Biotechnology Co.,Ltd
|
2025-08-19 | |
| $31.00/1kg |
VIP2Y
|
Henan Fengda Chemical Co., Ltd
|
2024-03-25 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY